Plan B sales expected to rise
This article was originally published in The Tan Sheet
Executive SummaryAs awareness of the nonprescription emergency contraceptive increases among younger women, manufacturer Barr Labs became a "top pick" by analysts who forecast Plan B sales in 2008 will reach $122 million, exceeding previous estimates of $90 million in 2008, according to Friedman, Billings, Ramsey analysts. FBR Research predicts Plan B sales will continue to grow in 2009 to $145 million...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.